Zhang Ying, Xu Xining, Ren Ximei, Li Zhenghong
Department of Orthopedics, The Affiliated Hospital Southwest Medical University, Sichuan, China.
Nursing Department, 940th Hospital of the Joint Logistics Support Force of the PLA, Gansu, China.
PLoS One. 2025 Jun 30;20(6):e0327011. doi: 10.1371/journal.pone.0327011. eCollection 2025.
The treatment of osteoporosis is challenged by limited bone regeneration and side effects. Bone marrow mesenchymal stem cell-derived extracellular vesicles (BMSC-EVs) have gained widespread attention as a potential therapeutic approach. This study aims to evaluate the effects of BMSC-EVs on bone density, trabecular microstructure, and biomechanical properties in animal models of osteoporosis, providing evidence to support clinical translation and mechanism exploration.
A systematic search was conducted in the PubMed, Cochrane, Web of Science, and Embase (inception to January 2025) databases for preclinical studies on BMSC-EV intervention in osteoporosis models. A random-effects model was used to synthesize and analyze seven key parameters (BMD, BV/TV, Tb.N, Tb.Sp, Tb.Th, Ct.Th, and ultimate load-bearing capacity). Subgroup analysis was performed based on species (rats/mice), EVs engineering targets/methods, injection frequency, and treatment duration. The quality of the studies was assessed using SYRCLE's risk of bias tool.
The meta-analysis of 10 studies (355 animals) showed that, compared to the control group, BMSC-EV treatment significantly increased BMD, BV/TV, Tb.N, Tb.Th, Ct.Th, and ultimate load-bearing capacity, while reducing Tb.Sp in the osteoporosis model. A publication bias was found in the summary analysis for Tb.N. However, sensitivity analysis confirmed that all summary results were relatively stable.
Compared to the control group, BMSC-EV treatment demonstrated positive effects in increasing BMD, improving trabecular microstructure, cortical thickness, and biomechanical properties in the osteoporosis model. However, clinical translation still requires standardized EV characterization and preclinical safety assessments.
骨再生受限和副作用给骨质疏松症的治疗带来了挑战。骨髓间充质干细胞衍生的细胞外囊泡(BMSC-EVs)作为一种潜在的治疗方法受到了广泛关注。本研究旨在评估BMSC-EVs对骨质疏松症动物模型的骨密度、小梁微观结构和生物力学性能的影响,为支持临床转化和机制探索提供证据。
在PubMed、Cochrane、Web of Science和Embase(从创刊到2025年1月)数据库中进行系统检索,以查找关于BMSC-EV干预骨质疏松症模型的临床前研究。采用随机效应模型对七个关键参数(骨密度、骨体积分数、骨小梁数量、骨小梁间距、骨小梁厚度、皮质厚度和极限承重能力)进行综合分析。根据物种(大鼠/小鼠)、细胞外囊泡工程靶点/方法、注射频率和治疗持续时间进行亚组分析。使用SYRCLE的偏倚风险工具评估研究质量。
对10项研究(355只动物)的荟萃分析表明,与对照组相比,BMSC-EV治疗显著提高了骨质疏松症模型中的骨密度、骨体积分数、骨小梁数量、骨小梁厚度、皮质厚度和极限承重能力,同时降低了骨小梁间距。在骨小梁数量的汇总分析中发现了发表偏倚。然而,敏感性分析证实所有汇总结果相对稳定。
与对照组相比,BMSC-EV治疗在提高骨质疏松症模型的骨密度、改善小梁微观结构、皮质厚度和生物力学性能方面显示出积极效果。然而,临床转化仍需要标准化的细胞外囊泡表征和临床前安全性评估。